



# ESC GUIDELINES DESK REFERENCE

ESC Committee for Practice Guidelines

To improve the quality of clinical practice and patient care in Europe



## COMPENDIUM OF ESC GUIDELINES 2007

For more information  
[www.escardio.org](http://www.escardio.org)



# Compendium of ESC Guidelines 2007

768350

UNIVERSITATEA DE STAT DE MEDICINĂ ȘI FARMACIE  
„NICOLAE TESTEMIȚANU”  
BIBLIOTECA  
ȘTIINȚIFICĂ MEDICALĂ

SL2



Wolters Kluwer  
Health

Lippincott  
Williams & Wilkins

# CONTENTS

Preface .....	XI
Silvia G Priori and Alec Vahanian .....	
Foreword .....	XIII
Michal Tendera and Kim Fox .....	
Guidelines overview .....	XV

---

## Section I: Prevention of Cardiovascular Disease ..... 1

---

1. Cardiovascular Disease Prevention in Clinical Practice .....	3
The European Heart Health Charter and the Guidelines on Cardiovascular Disease Prevention .....	3
Why develop a preventive strategy in clinical practice? .....	5
What are the objectives of these guidelines? .....	5
People who stay healthy tend to have certain characteristics .....	5
What are the priorities for CVD prevention in clinical practice? .....	5
What are the objectives of CVD prevention? .....	6
When do I assess cardiovascular risk? .....	6
Why do the Guidelines stress the assessment of total CVD risk? .....	6
How do I assess CVD risk quickly and easily? .....	7
Assessing cardiovascular risk: What are the components? .....	7
How do I use the SCORE charts to assess CVD risk in asymptomatic persons? .....	7
Risk estimation using SCORE: Qualifiers .....	8
10 year risk of fatal CVD in high risk regions of Europe .....	8
Relative risk chart .....	9
How do I manage the components of total CVD risk? .....	9
Total risk CVD management: A key message .....	10
Managing total cardiovascular risk .....	10
Why do people find it hard to change their life? .....	10
When to prescribe cardio-protective drugs in addition to those used to treat blood pressure, lipids and diabetes? .....	13
Why screen close relatives? .....	13
What would make the practice of CVD prevention easier? .....	13

---

## Section II: Hypertension ..... 15

---

1. The Management of Arterial Hypertension .....	17
Arterial hypertension .....	17
Total cardiovascular (CV) risk .....	18
Stratification of total CV risk .....	18
Clinical variables that should be used to stratify total CV risk .....	19
Diagnostic evaluation .....	20
Blood pressure (BP) measurement .....	20
Ambulatory and home BP measurements .....	20
Diagnostic evaluation: medical history and physical examination .....	21
Laboratory investigation .....	21
Searching for subclinical organ damage .....	22
Evidence on the benefit of antihypertensive treatment .....	22
Initiation of BP lowering therapy .....	23
Goals of treatment .....	23
Lifestyle changes .....	24
Choice of antihypertensive drugs .....	24
Conditions favouring the use of some antihypertensive drugs versus other .....	25
Contra-indications to use certain antihypertensive drugs .....	25
Monotherapy versus combination therapy .....	26
Possible combinations between some classes of antihypertensive drugs .....	26
Antihypertensive treatment in special groups .....	26



Hypertension in women	28
The metabolic syndrome	29
Resistant hypertension	29
Hypertensive emergencies	30
Treatment of associated risk factors	30
Patients' follow-up	30
How to improve compliance with blood pressure lowering therapy	31

---

**Section III: Diabetic Heart Disease . . . . . 33**

---

<b>1.</b>	Diabetes, Pre-diabetes and Cardiovascular Diseases	35
	Preamble	35
	Introduction	36
	Definition, classification, and screening of diabetes and pre-diabetic glucose abnormalities	38
	Epidemiology of diabetes, IGH, and cardiovascular risk	40
	Identification of subjects at high risk for CVD or diabetes	40
	Treatment to reduce cardiovascular risk	42
	Management of cardiovascular disease	45
	Heart failure and diabetes	48
	Arrhythmias, atrial fibrillation and sudden cardiac death	48
	Peripheral and cerebrovascular disease	49
	Intensive care	50
	Health economics and diabetes	51
	Glossary of abbreviations	52
	Trials and studies acronyms	52
	References	52

---

**Section IV: Coronary Heart Disease . . . . . 53**

---

<b>1.</b>	Diagnosis and Treatment of Non-ST-segment Elevation Acute Coronary Syndromes	55
	Introduction	55
	Definitions	55
	Epidemiology and natural history	56
	Pathophysiology	56
	Diagnosis and risk assessment	57
	Treatment	59
	Complications and their management	63
	Special populations and conditions	64
	Management strategies	66
<b>2.</b>	Acute Myocardial Infarction (AMI)	69
	Introduction	69
	Emergency care	70
	Pre-hospital or early in-hospital care	70
	Management of the later in-hospital course in the acute phase	74
<b>3.</b>	Stable Angina Pectoris	77
	Introduction	77
	Diagnosis and Assessment	78
	Treatment	82
	Special Diagnostic Considerations: Angina with "normal" coronary arteries	89
<b>4.</b>	Percutaneous Coronary Interventions (PCI)	91
	Introduction and Definitions	91
	Indications for PCI	92
	Adjunctive Medications for PCI	96
	Adjunctive Devices for PCI	97
	Drug-eluting Stents (DES)	98

---

**Section V: Myocardial Disease . . . . . 101**

---

1.	Hypertrophic Cardiomyopathy . . . . .	103
	Introduction . . . . .	103
	Genetics . . . . .	103
	Presentation . . . . .	103
	Diagnosis . . . . .	103
	Differential diagnosis . . . . .	104
	Pathophysiological features . . . . .	104
	Examination . . . . .	104
	Treatment . . . . .	104
	Medical therapy . . . . .	104
	Treatment options for drug-refractory patients . . . . .	105
	Drugs for “end stage” . . . . .	106
	Infective endocarditis prophylaxis . . . . .	106
	Pregnancy . . . . .	106
	Prevention of sudden cardiac death . . . . .	107
	Exercise recommendations . . . . .	107
	Screening . . . . .	107
	HCM in the elderly . . . . .	107

---

**Section VI: Pericardial Disease . . . . . 109**

---

1.	Management of Pericardial Diseases . . . . .	111
	Introduction . . . . .	111
	Acute pericarditis . . . . .	112
	Pericardial effusion and cardiac tamponade . . . . .	115
	Constrictive pericarditis . . . . .	117
	Viral pericarditis . . . . .	119
	Bacterial pericarditis . . . . .	119
	Pericarditis in renal failure . . . . .	120
	Auto reactive pericarditis and pericardial involvement in systemic autoimmune diseases . . . . .	120
	The post-cardiac injury syndrome: postpericardiotomy syndrome . . . . .	121
	Post-infarction pericarditis . . . . .	121
	Traumatic pericardial effusion . . . . .	121
	Haemopericardium in aortic dissection . . . . .	122
	Neoplastic pericarditis . . . . .	122
	Pericardial effusion in pregnancy . . . . .	122
	Foetal pericardial effusion . . . . .	122
	Drug- and toxin-related pericardial disease . . . . .	123

---

**Section VII: Congenital Heart Disease . . . . . 125**

---

1.	Grown Up Congenital Heart Disease . . . . .	127
	Introduction & background . . . . .	127
	Organisation of care . . . . .	128
	Medical issues . . . . .	128
	Surgical issues . . . . .	137
	Psychosocial issues . . . . .	137
	Specific lesions . . . . .	139

2.	Neonatal Electrocardiogram	155
	Introduction	155
	Normal electrocardiogram in the newborn	155
	Abnormal electrocardiogram in the newborn	157

---

**Section VIII: Pregnancy and Heart Disease** . . . . . **167**

---

1.	Cardiovascular Disease during Pregnancy	169
	Introduction	169
	Physiological changes during pregnancy	169
	In general	170
	Congenital heart disease	170
	Marfan syndrome and other inherited conditions affecting the aorta	171
	Acquired valvular heart disease	171
	Cardiomyopathies	172
	Arrhythmias	172
	Hypertensive disorders	173

---

**Section IX: Valvular Heart Disease** . . . . . **175**

---

1.	Valvular Heart Disease	177
	Introduction	177
	Patient evaluation	178
	Indications for treatment in native valve diseases	179
	Prosthetic valves	186
	Management during non-cardiac surgery	189
	Management during pregnancy	189

---

**Section X: Infective Endocarditis** . . . . . **191**

---

1.	Infective Endocarditis	193
	Introduction	193
	Definitions	193
	Terminology	193
	Prevention of infective endocarditis	194
	Diagnosis	196
	Treatment and management	197
	Management of complications	199
	Surgery for active NVE	200
	Surgery for active PVE	200
	List of abbreviations	200

---

**Section XI: Heart Failure** . . . . . **201**

---

1.	Acute Heart Failure (AHF)	203
	Introduction	203
	Definition, aetiology and mechanisms	204
	Classifications	204
	Diagnostic algorithm	206
	Laboratory tests	206
	Treatment goals	207
	Initial management	207



Invasive monitoring	208
Specific pharmacological treatments	208
Treatment of rhythm disturbances	209
Conditions requiring surgical management	209
Glossary	211
<b>2. Chronic Heart Failure (CHF)</b>	<b>213</b>
Definition and descriptive terms	213
Diagnosis	214
Treatment of heart failure caused by left ventricular systolic dysfunction	215
Choice and timing of pharmacological therapy	220
Management of heart failure with preserved left ventricular ejection fraction (PLVEF)	221
Arrhythmias	221
Care and follow-up	222

---

## **Section XII: Pulmonary Arterial Hypertension** . . . . . **223**

---

<b>1. Pulmonary Arterial Hypertension (PAH)</b>	<b>225</b>
Definitions and classification	225
Diagnosis of pulmonary arterial hypertension	226
Evaluation of severity	230
Treatment of pulmonary arterial hypertension	230
Treatment algorithm	233
Associated conditions	235
Paediatric pulmonary arterial hypertension (PPAH)	237
Glossary	238

---

## **Section XIII: Arrhythmias** . . . . . **239**

---

<b>1. Supraventricular Arrhythmias (SVA)</b>	<b>241</b>
Introduction	241
General evaluation and management	242
Specific arrhythmias	243
References	258
<b>2. Atrial Fibrillation (AF)</b>	<b>259</b>
Introduction	259
Classification of AF	260
Epidemiology and prognosis	261
Clinical evaluation	261
Proposed management strategies	261
Recommendations	271
<b>3. Management of Syncope</b>	<b>279</b>
Evaluation of patients with syncope	279
Diagnostic tests	281
Treatment	285
Situations in which ICD therapy is likely to be useful	286
Syncope facility ("Syncope unit")	286

4.	Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death	287
	Introduction	287
	Incidence of sudden cardiac death	290
	Clinical presentations of patients with ventricular arrhythmias and sudden cardiac death	290
	General evaluation of patients with documented or suspected ventricular arrhythmias	291
	Therapies for ventricular arrhythmias	293
	Acute management of specific arrhythmias	293
	Ventricular arrhythmia and sudden cardiac death related to specific pathology	296
	Ventricular arrhythmias associated with cardiomyopathies	298
	Heart failure	299
	Genetic arrhythmia syndromes	300
	Ventricular arrhythmias and sudden cardiac death related to specific populations	302
	Glossary	305
	Index	311
	ESC website link	325